SOLVAY'S FLUVOXAMINE MALEATE IS FIRST DRUG APPROVED FOR TREATMENT OF SOCIAL ANXIETY DISORDER IN JAPAN

SOLVAY PHARMACEUTICALS announces today that Meiji Seika Kaisha Ltd. (Tokyo) and Solvay Seiyaku K. K. (Tokyo) obtained approval of additional indication of Social Anxiety Disorder (Social Phobia) from Japan's Ministry of Health, Labour, and Welfare on fluvoxamine maleate (DEPROMEL/ Meiji Seika, LUVOX/ Solvay Seiyaku) on October 11.

Euronext (http://www.euronext.com/news/companypressrelease/0,4616,1700631_11894_665863114,00.html)